YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
T Cells Gain Phagocytic Function via Specific Antigen RecognitionThe research team engineered CD8+ Jurkat T cells to express SVAR16 ...
Complementary biochemical and structural findings reveal molecular principles underlying substrate selectivity by a model hyaluronan synthase.
Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results